XML 118 R98.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Details)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
wholesaler
segment
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Segment Reporting Information [Line Items]                      
Number of operating segments | segment                 2    
Number of wholesalers | wholesaler                 3    
Revenue $ 6,438.6 $ 6,061.9 $ 6,355.2 $ 5,700.0 $ 6,160.7 $ 5,658.0 $ 5,824.3 $ 5,228.3 $ 24,555.7 $ 22,871.3 $ 21,222.1
Total segment profits                 3,795.7 2,197.4 3,374.0
Amortization of intangible assets (Note 8)                 (558.7) (683.4) (687.9)
Asset impairment, restructuring, and other special charges (Note 5) (246.0) (83.3) (74.4) (78.3) (1,003.2) (406.5) (50.0) (213.9) (482.0) (1,673.6) (382.5)
Venezuela charge (Note 17)                 0.0 0.0 203.9
Acquired in-process research and development (Note 3) (329.4) (30.0) (1,624.5) 0.0 (50.0) (205.0) 0.0 (857.6) (1,983.9) (1,112.6) (30.0)
Inventory fair value adjustment related to acquisition of BIVIVP (Note 3) (1,593.7) $ (1,562.3) $ (1,702.7) $ (1,571.3) (1,644.9) $ (1,586.3) $ (1,571.7) $ (1,347.9) (6,430.0) (6,150.8) (5,710.1)
Other—net, (income) expense (Note 17)                 (74.8) (300.5) (112.8)
Consolidated income before taxes                 3,795.7 2,197.4 3,374.0
Long-lived assets 9,532.1       9,480.3       9,532.1 9,480.3 8,994.5
United States                      
Segment Reporting Information [Line Items]                      
Revenue                 13,875.2 12,785.1 11,506.2
Long-lived assets 4,946.6       5,013.4       4,946.6 5,013.4 4,984.6
Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 10,680.5 10,086.3 9,715.9
Europe                      
Segment Reporting Information [Line Items]                      
Revenue                 4,231.1 3,943.2 3,768.1
Long-lived assets 2,708.1       2,550.1       2,708.1 2,550.1 2,140.7
JAPAN                      
Segment Reporting Information [Line Items]                      
Revenue                 2,493.7 2,419.7 2,330.9
Long-lived assets 181.9       155.1       181.9 155.1 92.4
Other foreign countries                      
Segment Reporting Information [Line Items]                      
Revenue                 3,955.7 3,723.3 3,616.9
Long-lived assets $ 1,695.5       $ 1,761.7       1,695.5 1,761.7 1,776.8
Human pharmaceutical products                      
Segment Reporting Information [Line Items]                      
Total depreciation expense and software amortization included in segment profits                 934.0 789.8 723.4
Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 12,352.2 11,274.0 9,941.7
Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 9,061.0 8,511.7 8,122.2
Animal health products                      
Segment Reporting Information [Line Items]                      
Total depreciation expense and software amortization included in segment profits                 111.3 102.7 89.9
Animal health products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 1,523.0 1,511.1 1,564.5
Animal health products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 1,619.5 1,574.5 1,593.7
Endocrinology | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 7,511.6 6,373.0 4,831.9
Endocrinology | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 4,190.5 3,712.2 3,250.9
Trulicity | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 2,515.8 1,609.8 737.6
Trulicity | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 683.3 419.9 187.9
Humalog | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 1,787.8 1,717.8 1,685.2
Humalog | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 1,208.7 1,147.4 1,083.6
Humulin | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 910.2 884.6 861.8
Humulin | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 421.2 450.7 504.1
Forteo | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 757.9 965.2 770.5
Forteo | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 817.7 783.8 729.4
Basaglar                      
Segment Reporting Information [Line Items]                      
Revenue                 801.2 432.1 86.1
Basaglar | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 622.8 311.1 15.8
Basaglar | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 178.5 121.0 70.3
Jardiance                      
Segment Reporting Information [Line Items]                      
Revenue                 658.3 447.5 201.9
Jardiance | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 400.2 290.4 144.5
Jardiance | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 258.1 157.0 57.4
Trajenta                      
Segment Reporting Information [Line Items]                      
Revenue                 574.7 537.9 436.6
Trajenta | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 224.2 213.2 165.9
Trajenta | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 350.5 324.7 270.7
Other Endocrinology | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 292.7 380.9 450.6
Other Endocrinology | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 272.5 307.7 347.5
Oncology: | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 2,403.2 2,050.4 1,975.1
Oncology: | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 1,857.3 1,761.6 1,746.8
Alimta | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 1,131.0 1,034.3 1,101.0
Alimta | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 1,001.9 1,028.2 1,182.3
Erbitux                      
Segment Reporting Information [Line Items]                      
Revenue                 635.3 645.9 687.0
Erbitux | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 531.6 541.7 581.1
Erbitux | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 103.8 104.2 105.9
Cyramza® | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 291.5 278.8 270.1
Cyramza® | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 529.9 479.6 344.0
Other Oncology | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 449.1 195.6 22.9
Other Oncology | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 221.7 149.6 114.6
Cardiovascular: | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 1,355.7 1,722.7 1,991.4
Cardiovascular: | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 898.6 1,148.5 1,234.0
Cialis | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 1,129.2 1,358.6 1,469.5
Cialis | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 722.7 964.5 1,002.1
Effient | Human pharmaceutical products                      
Segment Reporting Information [Line Items]                      
Revenue                 122.2 388.9 535.2
Effient | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 68.1 340.1 465.6
Effient | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 54.1 48.8 69.6
Other Cardiovascular | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 158.4 24.0 56.3
Other Cardiovascular | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 121.8 135.2 162.3
Neuroscience: | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 277.4 591.0 989.9
Neuroscience: | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 1,543.3 1,580.1 1,730.4
Strattera® | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 89.7 284.9 534.9
Strattera® | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 361.1 333.3 319.8
Cymbalta | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 54.3 114.9 269.3
Cymbalta | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 653.7 642.2 661.2
Zyprexa® | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 36.2 75.5 69.8
Zyprexa® | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 435.1 505.7 655.5
Other Neuroscience | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 97.2 115.7 115.9
Other Neuroscience | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 93.4 98.9 93.9
Immunology: | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 745.4 486.0 110.8
Immunology: | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 394.6 119.0 2.3
Taltz | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 738.7 486.0 110.8
Taltz | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 198.7 73.2 2.3
Other Immunology | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 6.7 0.0 0.0
Other Immunology | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 195.9 45.8 0.0
Other human pharmaceutical products | Human pharmaceutical products | United States                      
Segment Reporting Information [Line Items]                      
Revenue                 58.7 50.9 42.6
Other human pharmaceutical products | Human pharmaceutical products | Outside U.S.                      
Segment Reporting Information [Line Items]                      
Revenue                 $ 176.6 $ 190.3 $ 157.8
Minimum | Sales Revenue, Goods, Net                      
Segment Reporting Information [Line Items]                      
Concentration risk, percentage                 11.00% 12.00% 11.00%
Minimum | Accounts Receivable                      
Segment Reporting Information [Line Items]                      
Concentration risk, percentage                 14.00% 14.00%  
Maximum | Sales Revenue, Goods, Net                      
Segment Reporting Information [Line Items]                      
Concentration risk, percentage                 18.00% 18.00% 17.00%
Maximum | Accounts Receivable                      
Segment Reporting Information [Line Items]                      
Concentration risk, percentage                 22.00% 22.00%  
Adjustment to Return Reserve | Cymbalta | Human pharmaceutical products                      
Segment Reporting Information [Line Items]                      
Revenue                     $ 175.0
Operating Segments                      
Segment Reporting Information [Line Items]                      
Total segment profits                 $ 6,825.1 $ 5,701.0 4,673.7
Consolidated income before taxes                 6,825.1 5,701.0 4,673.7
Total depreciation expense and software amortization included in segment profits                 1,045.3 892.5 813.3
Operating Segments | Human pharmaceutical products                      
Segment Reporting Information [Line Items]                      
Total segment profits                 6,217.8 5,139.7 4,010.0
Consolidated income before taxes                 6,217.8 5,139.7 4,010.0
Operating Segments | Animal health products                      
Segment Reporting Information [Line Items]                      
Total segment profits                 607.3 561.3 663.7
Consolidated income before taxes                 607.3 561.3 663.7
Corporate, Non-Segment                      
Segment Reporting Information [Line Items]                      
Total segment profits                 3,795.7 2,197.4 3,374.0
Amortization of intangible assets (Note 8)                 (546.0) (674.8) (683.3)
Asset impairment, restructuring, and other special charges (Note 5)                 (482.0) (1,673.6) (382.5)
Venezuela charge (Note 17)                 0.0 0.0 (203.9)
Acquired in-process research and development (Note 3)                 (1,983.9) (1,112.6) (30.0)
Inventory fair value adjustment related to acquisition of BIVIVP (Note 3)                 0.0 (42.7) 0.0
Other—net, (income) expense (Note 17)                 (17.5) 0.0 0.0
Consolidated income before taxes                 $ 3,795.7 $ 2,197.4 $ 3,374.0